Guard Therapeutics: Uncertain future - Redeye
Bildkälla: Stockfoto

Guard Therapeutics: Uncertain future - Redeye

Redeye returns with a new note after gaining more insights from Monday’s webcast. Following the failure of the phase IIb study POINTER, we lower our valuation substantially and now ground our valuation scenarios on strategic alternatives.

Redeye returns with a new note after gaining more insights from Monday’s webcast. Following the failure of the phase IIb study POINTER, we lower our valuation substantially and now ground our valuation scenarios on strategic alternatives.
Börsvärldens nyhetsbrev